LENSAR (LNSR)
(Delayed Data from NSDQ)
$5.12 USD
-0.03 (-0.58%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $5.18 +0.06 (1.17%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LNSR 5.12 -0.03(-0.58%)
Will LNSR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LNSR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LNSR
LENSAR, Inc. (LNSR) Reports Q1 Loss, Tops Revenue Estimates
LNSR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for LNSR
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), AbbVie (ABBV) and LENSAR (LNSR)
Lensar management to meet virtually with BTIG
Lensar management to meet virtually with BTIG
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), LENSAR (LNSR)